Your browser doesn't support javascript.
loading
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler, David C; Stefánsson, Bergur V; Jongs, Niels; Chertow, Glenn M; Greene, Tom; Hou, Fan Fan; McMurray, John J V; Correa-Rotter, Ricardo; Rossing, Peter; Toto, Robert D; Sjöström, C David; Langkilde, Anna Maria; Heerspink, Hiddo J L.
Afiliación
  • Wheeler DC; Department of Renal Medicine, University College London, London, UK; The George Institute for Global Health, Sydney, NSW, Australia. Electronic address: d.wheeler@ucl.ac.uk.
  • Stefánsson BV; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Chertow GM; Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  • Greene T; Study Design and Biostatistics Center, University of Utah Health Sciences, Salt Lake City, UT, USA.
  • Hou FF; Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.
  • McMurray JJV; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.
  • Correa-Rotter R; National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
  • Rossing P; Steno Diabetes Center Copenhagen, Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Toto RD; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
  • Sjöström CD; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Langkilde AM; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Heerspink HJL; The George Institute for Global Health, Sydney, NSW, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Lancet Diabetes Endocrinol ; 9(1): 22-31, 2021 01.
Article en En | MEDLINE | ID: mdl-33338413
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Bencidrilo / Diabetes Mellitus Tipo 2 / Glucósidos / Insuficiencia Cardíaca / Fallo Renal Crónico Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Bencidrilo / Diabetes Mellitus Tipo 2 / Glucósidos / Insuficiencia Cardíaca / Fallo Renal Crónico Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido